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We read with interest the article by Sazonova et al. about
their study of 700 patients with atherosclerosis who were
investigated for the presence or absence of 11 mtDNA vari-
ants [1]. The authors found that the mtDNA variants
m.652delG, m.3336C>T, m.12315G>A, m.14459G>A, and
m.15059G>A could serve as biomarkers for the assessment
of future atherosclerotic risk in the general population [1].
We have the following comments and concerns.
We do not agree with the statement that the above-
mentioned mtDNA variants could be useful as a biomarker
of atherosclerosis [1] for several reasons. First, hetero-
plasmy rates were determined only in blood lymphocytes
[1]. It is well known that heteroplasmy rates vary consider-
ably between different tissues and that heteroplasmy rates
in lymphocytes do not reflect the mutation load in clinically
or instrumentally affected tissues. Were the heteroplasmy
rates determined in tissues other than lymphocytes? Het-
eroplasmy rates from vascular endothelial cells or vascular
smooth muscle cells would be of interest, at least in an ani-
mal model of atherosclerosis.
Second, it is not mentioned how many of the included
patients had arterial hypertension, diabetes, and hyperlipid-
emia or how many were smoking. Since these classical risk
factors for atherosclerosis were not assessed, it cannot be
excluded that plaque burden in the carotid arteries is in fact
attributable to any of the classical risk factors and has noth-
ing to do with the amount of mtDNA variants.
Third, more specific risk factors for atherosclerosis,
such as high-sensitivity C-reactive protein, the telomere
length, lipid oxidation products (MDA-modified collagen
type IV IgM and IgG antibodies), hyperuricemia, TNF-alpha,
and IL-15 polymorphism, were not assessed. They also can
have a significant influence on the severity and progression
of atherosclerosis.
Fourth, we need to be informed about the medication
these patients were regularly taking, since there are a number
of compounds which potentially increase the risk of athero-
sclerosis such as anabolic androgen steroids, testosterone gel,
antiretroviral agents, proton pump inhibitors, leptin, or anti-
epileptic drugs, particularly valproate and carbamazepine [2].
It would be also interesting to know how many of those
who carried an mtDNA variant also suffered from a mito-
chondrial disorder (MID) at inclusion or how many devel-
oped a MID during follow-up. It is well appreciated that
MIDs manifest not only in the arteries but also in the brain,
spinal cord, eyes, ears, endocrine organs, heart, lungs, intes-
tines, kidneys, blood, bones, or skin [3]. In the included
patients, were any of these organs or tissues affected alone
or in combination? In the included patients, was the family
history positive for a MID?
It is also well known that large and small arteries may be
affected in MIDs manifesting as dissection of the carotid
arteries [4–6], aneurysm formation [5], ectasia of the aorta
[7], microangiopathy of the retinal arteries [8], spontaneous
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rupture of the aorta [9], premature atherosclerosis [10], arte-
riovenous malformations [11], and arterial hypertension
[12]. How many of the included patients manifested with
arteriopathy other than atherosclerosis?
Overall, this interesting study could profit not only
from more widespread genetic studies but also from the
assessment of common and uncommon risk factors for
atherosclerosis to exclude influences other than the amount
of mtDNA variants tested on the atherosclerotic risk in the
general population.
Conflicts of Interest
There are no conflicts of interest.
Authors’ Contributions
Josef Finsterer is responsible for the design, literature search,
and discussion and for the first draft. Sinda Zarrouk-
Mahjoub is responsible for the literature search, discussion,
and critical comments. Both authors contributed equally.
References
[1] M. A. Sazonova, V. V. Sinyov, A. I. Ryzhkova et al., “Role of
mitochondrial genome mutations in pathogenesis of carotid
atherosclerosis,” Oxidative Medicine and Cellular Longevity,
vol. 2017, Article ID 6934394, 7 pages, 2017.
[2] Q. Lai, C. Shen, Y. Zheng, Y. Zhang, Y. Guo, and M. Ding,
“Effects of antiepileptic drugs on the carotid artery intima-
media thickness in epileptic patients,” Journal of Clinical
Neurology, vol. 13, no. 4, pp. 371–379, 2017.
[3] J. Finsterer and S. Zarrouk-Mahjoub, “Mitochondrial
vasculopathy,” World Journal of Cardiology, vol. 8, no. 5,
pp. 333–339, 2016.
[4] A. V. Sakharova, L. A. Kalashnikova, R. P. Chaĭkovskaia et al.,
“Morphological signs of mitochondrial cytopathy in skeletal
muscles and micro-vessel walls in a patient with cerebral artery
dissection associated with MELAS syndrome,” Arkhiv Patolo-
gii, vol. 74, no. 2, pp. 51–56, 2012.
[5] R. C. C. Ryther, Y. A. Cho-Park, and J. W. Lee, “Carotid dissec-
tion in mitochondrial encephalomyopathy with lactic acidosis
and stroke-like episodes,” Journal of Neurology, vol. 258, no. 5,
pp. 912–914, 2011.
[6] L. A. Kalashnikova, L. A. Dobrynina, A. V. Sakharova et al.,
“The A3243G mitochondrial DNA mutation in cerebral
artery dissections,” Zhurnal Nevrologii i Psikhiatrii Imeni
S.S. Korsakova, vol. 112, no. 1, pp. 84–89, 2012.
[7] N. Brunetti-Pierri, R. Pignatelli, N. Fouladi et al., “Dilation of
the aortic root in mitochondrial disease patients,” Molecular
Genetics and Metabolism, vol. 103, no. 2, pp. 167–170, 2011.
[8] I. Martin-Kleiner, J. Gabrilovac, M. Bradvica et al., “Leber’s
hereditary optic neuroretinopathy (LHON) associated with
mitochondrial DNA point mutation G11778A in two Croatian
families,” Collegium Antropologicum, vol. 30, no. 1,
pp. 171–174, 2006.
[9] S. H. K. Tay, D. R. Nordli Jr, E. Bonilla et al., “Aortic rupture in
mitochondrial encephalopathy, lactic acidosis, and stroke-like
episodes,” Archives of Neurology, vol. 63, no. 2, pp. 281–283,
2006.
[10] J. Finsterer and C. Stöllberger, “Leriche-syndrome despite
regular sport and non-compaction suggest neuromuscular
disease,” International Journal of Cardiology, vol. 191,
pp. 15–17, 2015.
[11] J. Fujitake, H. Mizuta, H. Fujii et al., “Leber’s hereditary optic
neuropathy with intracranial arteriovenous malformation: a
case report,” Acta Neurologica Belgica, vol. 102, no. 2,
pp. 82–86, 2002.
[12] L. Wang, Z. Dong, W. Lin, R. Gao, C. Chen, and J. Xu,
“Molecular characterization of a pedigree carrying the
hypertension-associated mitochondrial tRNAGln T4363C
mutation,” Molecular Medicine Reports, vol. 16, no. 5,
pp. 6029–6033, 2017.
2 Oxidative Medicine and Cellular Longevity
